Mechanisms of tumor development and anti-angiogenic therapy in glioblastoma multiforme

Neurologia Medico-Chirurgica

Volumn 53, Issue 11, 2013, Pages 755-763

  Onishi, Manabu ^a   Kurozumi, Kazuhiko ^a   Ichikawa, Tomotsugu ^a   Date, Isao ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Bevacizumab; Cilengitide; Invasion

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; BEVACIZUMAB; CASPASE 8; CILENGITIDE; CYSTEINE RICH PROTEIN 61; HYPOXIA INDUCIBLE FACTOR 1; LIPOCORTIN 2; MICROTUBULE ASSOCIATED PROTEIN 2; PLACEBO; TEMOZOLOMIDE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; VITRONECTIN RECEPTOR; VON WILLEBRAND FACTOR; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; SNAKE VENOM; TUMOR PROTEIN; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ARTICLE; BASEMENT MEMBRANE; CANCER RADIOTHERAPY; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; DNA MICROARRAY; DRUG EFFICACY; DRUG TOLERABILITY; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEOMICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); THERAPY RESISTANCE; TUMOR INVASION; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; CELL ADHESION; DRUG EFFECTS; MULTIMODALITY CANCER THERAPY; NEOVASCULARIZATION, PATHOLOGIC; PHYSIOLOGY; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BEVACIZUMAB; BRAIN NEOPLASMS; CELL ADHESION; COMBINED MODALITY THERAPY; GLIOBLASTOMA; HUMANS; INTEGRIN ALPHAVBETA3; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; SNAKE VENOMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84888266304     PISSN: 04708105     EISSN: 13498029     Source Type: Journal    
DOI: 10.2176/nmc.ra2013-0200     Document Type: Article

References (68)

1. Abdollahi A, Griggs DW, Zieher H, Roth A, Lipson KE, Saffrich R, Gröne HJ, Hallahan DE, Reisfeld RA, Debus J, Niethammer AG, Huber PE: Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 11: 6270-6279, 2005
2. Agha CA, Ibrahim S, Hassan A, Elias DA, Fathallah-Shaykh HM: Bevacizumab is active as a single agent against recurrent malignant gliomas. Anticancer Res 30: 609-611, 2010
3. Beadle C, Assanah MC, Monzo P, Vallee R, Rosenfeld SS, Canoll P: The role of myosin II in glioma invasion of the brain. Mol Biol Cell 19: 3357-3368, 2008
4. Bello L, Giussani C, Carrabba G, Pluderi M, Costa F, Bikfalvi A: Angiogenesis and invasion in gliomas. Cancer Treat Res 117: 263-284, 2004
5. Bergers G, Hanahan D: Modes of resistance to antiangiogenic therapy. Nat Rev Cancer 8: 592-603, 2008
6. Bergers G, Song S: The role of pericytes in bloodvessel formation and maintenance. Neuro-oncology 7: 452-464, 2005
7. Bornhauser BC, Lindholm D: MSAP enhances migration of C6 glioma cells through phosphorylation of the myosin regulatory light chain. Cell Mol Life Sci 62: 1260-1266, 2005
8. Brahimi-Horn C, Berra E, Pouysségur J: Hypoxia: the tumor's gateway to progression along the angiogenic pathway. Trends Cell Biol 11: S32-36, 2001
9. Brem S, Cotran R, Folkman J: Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst 48: 347-356, 1972
10. Brooks PC, Clark RA, Cheresh DA: Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264: 569-571, 1994
11. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA: Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79: 1157-1164, 1994
12. Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL: Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 62: 4263-4272, 2002
13. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 407: 249-257, 2000
14. Chamberlain MC, Johnston SK: Salvage therapy with single agent bevacizumab for recurrent glioblastoma. J Neurooncol 96: 259-269, 2010
15. de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, Conrad CA: Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro-oncology 12: 233-242, 2010
16. de Vries NA, Beijnen JH, van Tellingen O: High-grade glioma mouse models and their applicability for preclinical testing. Cancer Treat Rev 35: 714-723, 2009
17. Del Maestro RF, Megyesi JF, Farrell CL: Mechanisms of tumor-associated edema: a review. Can J Neurol Sci 17: 177-183, 1990
18. Eskens FA, Dumez H, Hoekstra R, Perschl A, Brindley C, Böttcher S, Wynendaele W, Drevs J, Verweij J, van Oosterom AT: Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 39: 917-926, 2003
19. Esser S, Lampugnani MG, Corada M, Dejana E, Risau W: Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J Cell Sci 111 (Pt 13): 1853-1865, 1998
20. Ferrara N, Kerbel RS: Angiogenesis as a therapeutic target. Nature 438: 967-974, 2005
21. Forsyth PA, Wong H, Laing TD, Rewcastle NB, Morris DG, Muzik H, Leco KJ, Johnston RN, Brasher PM, Sutherland G, Edwards DR: Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer 79: 1828-1835, 1999
22. Gilbert MR, Kuhn J, Lamborn KR, Lieberman F, Wen PY, Mehta M, Cloughesy T, Lassman AB, Deangelis LM, Chang S, Prados M: Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. J Neurooncol 106: 147-153, 2012
23. Goodenough DA, Goliger JA, Paul DL: Connexins, connexons, and intercellular communication. Annu Rev Biochem 65: 475-502, 1996
24. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996
25. Henriksson R, Bottomley A, Mason W, et al: Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase II study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM). 2013 ASCO Annual Meeting. Abstract 2005. Presented June 1, 2013
26. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ: Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284: 1994-1998, 1999
27. Inoue S, Ichikawa T, Kurozumi K, Maruo T, Onishi M, Yoshida K, Fujii K, Kambara H, Chiocca EA, Date I: Novel animal glioma models that separately exhibit two different invasive and angiogenic phenotypes of human glioblastomas. World Neurosurg 78: 670-682, 2012
28. Jain RK: Molecular regulation of vessel maturation. Nat Med 9: 685-693, 2003
29. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT: Angiogenesis in brain tumours. Nat Rev Neurosci 8: 610-622, 2007
30. Jiang BH, Rue E, Wang GL, Roe R, Semenza GL: Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 271: 17771-17778, 1996
31. Kevil CG, Payne DK, Mire E, Alexander JS: Vascular permeability factor/vascular endothelial cell growth factor-mediated permeability occurs through disorganization of endothelial junctional proteins. J Biol Chem 273: 15099-15103, 1998
32. Kim S, Bell K, Mousa SA, Varner JA: Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol 156: 1345-1362, 2000
33. Kireeva ML, Lam SC, Lau LF: Adhesion of human umbilical vein endothelial cells to the immediateearly gene product Cyr61 is mediated through integrin alphavbeta3. J Biol Chem 273: 3090-3096, 1998
34. Kurozumi K, Hardcastle J, Thakur R, Shroll J, Nowicki M, Otsuki A, Chiocca EA, Kaur B: Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. Mol Ther 16: 1382-1391, 2008
35. Kurozumi K, Hardcastle J, Thakur R, Yang M, Christoforidis G, Fulci G, Hochberg FH, Weissleder R, Carson W, Chiocca EA, Kaur B: Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst 99: 1768-1781, 2007
36. Lakka SS, Gondi CS, Rao JS: Proteases and glioma angiogenesis. Brain Pathol 15: 327-341, 2005
37. Lamszus K, Kunkel P, Westphal M: Invasion as limitation to anti-angiogenic glioma therapy. Acta Neurochir Suppl 88: 169-177, 2003
38. Leask A, Abraham DJ: All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci 119: 4803-4810, 2006
39. Leavesley DI, Ferguson GD, Wayner EA, Cheresh DA: Requirement of the integrin beta 3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen. J Cell Biol 117: 1101-1107, 1992
40. Lebelt A, Dziecioł J, Guziń ska-Ustymowicz K, Lemancewicz D, Zimnoch L, Czykier E: Angiogenesis in gliomas. Folia Histochem Cytobiol 46: 69-72, 2008
41. Lindahl P, Johansson BR, Levéen P, Betsholtz C: Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277: 242-245, 1997
42. Lopes MB: Angiogenesis in brain tumors. Microsc Res Tech 60: 225-230, 2003
43. MacDonald TJ, Taga T, Shimada H, Tabrizi P, Zlokovic BV, Cheresh DA, Laug WE: Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery 48: 151-157, 2001
44. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277: 55-60, 1997
45. Mandriota SJ, Seghezzi G, Vassalli JD, Ferrara N, Wasi S, Mazzieri R, Mignatti P, Pepper MS: Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J Biol Chem 270: 9709-9716, 1995
46. Maruo T, Ichikawa T, Kanzaki H, Inoue S, Kurozumi K, Onishi M, Yoshida K, Kambara H, Ouchida M, Shimizu K, Tamaru S, Chiocca EA, Date I: Proteomics-based analysis of invasion-related proteins in malignant gliomas. Neuropathology 33: 264-275, 2013
47. Mikkelsen T, Brodie C, Finniss S, Berens ME, Rennert JL, Nelson K, Lemke N, Brown SL, Hahn D, Neuteboom B, Goodman SL: Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int J Cancer 124: 2719-2727, 2009
48. Nagano O, Saya H: Mechanism and biological significance of CD44 cleavage. Cancer Sci 95: 930-935, 2004
49. Onishi M, Ichikawa T, Kurozumi K, Date I: Angiogenesis and invasion in glioma. Brain Tumor Pathol 28: 13-24, 2011
50. Onishi M, Ichikawa T, Kurozumi K, Fujii K, Yoshida K, Inoue S, Michiue H, Chiocca EA, Kaur B, Date I: Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models. Neuropathology 33: 162-174, 2013
51. Onishi M, Kurozumi K, Ichikawa T, Michiue H, Fujii K, Ishida J, Shimazu Y, Chiocca EA, Kaur B, Date I: Gene expression profiling of the anti-glioma effect of Cilengitide. Springerplus 2: 160, 2013
52. Rao JS, Yamamoto M, Mohaman S, Gokaslan ZL, Fuller GN, Stetler-Stevenson WG, Rao VH, Liotta LA, Nicolson GL, Sawaya RE: Expression and localization of 92 kDa type IV collagenase/gelatinase B (MMP-9) in human gliomas. Clin Exp Metastasis 14: 12-18, 1996
53. Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, Schiff D, Shapiro WR, Burdette-Radoux S, Dropcho EJ, Wittemer SM, Nippgen J, Picard M, Nabors LB: Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26: 5610-5617, 2008
54. Reifenberger G, Collins VP: Pathology and molecular genetics of astrocytic gliomas. J Mol Med 82: 656-670, 2004
55. Reiss Y, Machein MR, Plate KH: The role of angiopoietins during angiogenesis in gliomas. Brain Pathol 15: 311-317, 2005
56. Rooprai HK, McCormick D: Proteases and their inhibitors in human brain tumours: a review. Anticancer Res 17: 4151-4162, 1997
57. Salhia B, Rutten F, Nakada M, Beaudry C, Berens M, Kwan A, Rutka JT: Inhibition of Rho-kinase affects astrocytoma morphology, motility, and invasion through activation of Rac1. Cancer Res 65: 8792-8800, 2005
58. Sathornsumetee S, Reardon DA, Desjardins A, Quinn JA, Vredenburgh JJ, Rich JN: Molecularly targeted therapy for malignant glioma. Cancer 110: 13-24, 2007
59. Stupp R, Van Den Bent MJ, Erridge SC, Reardon DA, Hong Y, Wheeler H, Hegi M, Perry JR, Picard M, Weller M: Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: protocol of a multicenter, randomized, open-label, controlled phase II trial (CENTRIC). J Clin Oncol 28: 15s, 2010
60. Tate MC, Aghi MK: Biology of angiogenesis and invasion in glioma. Neurotherapeutics 6: 447-457, 2009
61. Tentori L, Dorio AS, Muzi A, Lacal PM, Ruffini F, Navarra P, Graziani G: The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma. Oncol Rep 19: 1039-1043, 2008
62. Wenger RH, Stiehl DP, Camenisch G: Integration of oxygen signaling at the consensus HRE. Sci STKE 2005: re12, 2005
63. Wesseling P, Ruiter DJ, Burger PC: Angiogenesis in brain tumors; pathobiological and clinical aspects. J Neurooncol 32: 253-265, 1997
64. Wild-Bode C, Weller M, Wick W: Molecular determinants of glioma cell migration and invasion. J Neurosurg 94: 978-984, 2001
65. Wong ML, Prawira A, Kaye AH, Hovens CM: Tumour angiogenesis: its mechanism and therapeutic implications in malignant gliomas. J Clin Neurosci 16: 1119-1130, 2009
66. Zagzag D, Amirnovin R, Greco MA, Yee H, Holash J, Wiegand SJ, Zabski S, Yancopoulos GD, Grumet M: Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis. Lab Invest 80: 837-849, 2000
67. Zagzag D, Goldenberg M, Brem S: Angiogenesis and blood-brain barrier breakdown modulate CT contrast enhancement: an experimental study in a rabbit brain-tumor model. AJR Am J Roentgenol 153: 141-146, 1989
68. Zagzag D, Hooper A, Friedlander DR, Chan W, Holash J, Wiegand SJ, Yancopoulos GD, Grumet M: In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis. Exp Neurol 159: 391-400, 1999